Years of research provides breast cancer patients with new hope
SANTA ROSA, Calif., Aug. 1, 2012 /PRNewswire/ -- Triple negative breast cancer is the most aggressive type of breast cancer and carries a very high risk of early -- and deadly -- metastasis. Current treatment for triple negative breast cancer is extremely limited. After completing the initial treatments for this deadly breast cancer, women have no viable options that can help them prevent recurrence and deadly metastasis. A new botanical formula may offer hope for this group of patients.
In a groundbreaking new study, this botanical formula has been shown to:
- inhibit highly aggressive and deadly breast cancer metastasis
- slow cancer growth
- suppress cancer genes
- be safe and non-toxic
Isaac Eliaz, M.D., co-author and researcher says, "Patients with triple negative breast cancer die from metastasis. This formula was able to alter the gene expression of highly aggressive metastatic breast cancer, dramatically decrease the metastatic process and slow growth of the primary tumor. Such a formula offers new hope to patients who are struggling to overcome an invasive, deadly disease which has been so difficult to treat. It may be especially important for breast cancer patients who finished conventional therapy, and are sent home without any treatment option that can prevent reoccurrence or spread of the cancer, as is the case with triple negative breast cancer. "
The study was conducted at the Cancer Research Laboratory, Methodist Research Institute, Indiana University Health. The researchers demonstrated that this specialized botanical formula slows highly aggressive triple negative human breast cancer and inhibits breast-to-lung metastasis in mice. Their study was presented at the prestigious annual meeting of the American Academy for Cancer Research and has just been published in the journal Oncology Reports. This is the third peer-reviewed study demonstrating the anticancer effects of this formula.
In this study researchers used a model which mimics the clinical progression of triple negative breast cancer as it develops and metastasizes in patients. They implanted highly invasive, triple-negative human breast cancer cells (MDA-MB-231) in the breast tissue of mice. The tested group was given the formula orally for four weeks; the control group received no treatment.
Results showed that the formula significantly decreased tumor growth and breast-to-lung metastasis. The cancer metastasized to the lungs in only 20% of the treated group as compared to 70% of the untreated, control group. Furthermore, in the treatment group that did metastasize, the number and size of the lesions was dramatically reduced in comparison to the control group.
Gene analysis showed that the formula down regulated (suppressed and reduced) two genes implicated in cancer metastasis -- PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4). These results further substantiate previous cancer cell studies published on this formula, which similarly demonstrated a down regulation of these cancer promoting genes.
Dr. Eliaz says, "The gene analysis performed in this study is very promising. It points to the potential of this formula to reduce the expression of these aggressive cancer genes in breast cancer patients."
This first of its kind formula includes ingredients that have been shown to have powerful anti-cancer properties.
- Medicinal mushrooms Trametes versicolor, Ganoderma lucidum, Phellinus linteus reduce cancer growth and invasiveness.
- Extracts from the botanicals Scutellaria barbata, Astragalus membranaceus and Curcuma longa induce programmed cell death (apoptosis) and reduce cancer metastasis.
- The flavonoid, quercetin, reduces cancer cell proliferation and helps suppress tumor growth.
- DIM (3, 3'-Diindolylmethane), an active component of cruciferous vegetables, reduces cancer growth, migration and invasiveness.
"In this study we showed that the formula is not toxic and its oral application significantly suppresses tumor size, and dramatically inhibits breast-to-lung cancer metastasis," says Daniel Sliva, Ph.D., lead author on the study. "This formula may be considered as a biological therapeutic agent against invasive breast cancer, including aggressive triple negative breast cancer. It can potentially increase survival of breast cancer patients who currently have limited or no treatment options available within conventional oncology."
Extensive research is continuing and human clinical trials are planned.Source: Jiang J, Thyagarajan-Sahu A, Loganathan J, Eliaz I, Terry C, Sandusky GE, Sliva D. BreastDefend prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer. Oncol Rep. 2012 Jul 26. doi: 10.3892/or.2012.1936.
About Better Health Publishing:
Better Health Publishing (BHP) focuses on the publication of key works promoting health and wellness. BHP believes that education and accessible information are the core components of a healthy and sustainable society.
SOURCE Better Health Publishing